X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13906) 13906
Publication (2387) 2387
Book Chapter (134) 134
Book Review (116) 116
Conference Proceeding (41) 41
Dissertation (33) 33
Book / eBook (5) 5
Government Document (4) 4
Data Set (3) 3
Magazine Article (2) 2
Reference (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9352) 9352
mtor (8426) 8426
humans (7346) 7346
animals (5086) 5086
oncology (3586) 3586
rapamycin (3529) 3529
tor serine-threonine kinases - metabolism (3356) 3356
cancer (3251) 3251
mice (2928) 2928
mammalian target (2905) 2905
cell biology (2797) 2797
phosphorylation (2628) 2628
female (2619) 2619
apoptosis (2592) 2592
signal transduction (2588) 2588
male (2436) 2436
autophagy (2219) 2219
cell line, tumor (2138) 2138
proteins (2068) 2068
biochemistry & molecular biology (2020) 2020
activation (1982) 1982
signal transduction - drug effects (1965) 1965
akt (1885) 1885
tor serine-threonine kinases - antagonists & inhibitors (1842) 1842
expression (1756) 1756
kinases (1721) 1721
growth (1689) 1689
proto-oncogene proteins c-akt - metabolism (1666) 1666
sirolimus - pharmacology (1616) 1616
article (1579) 1579
analysis (1445) 1445
pathway (1434) 1434
tor protein (1429) 1429
everolimus (1387) 1387
inhibition (1294) 1294
research (1216) 1216
tor serine-threonine kinases (1207) 1207
cell proliferation - drug effects (1204) 1204
pharmacology & pharmacy (1168) 1168
phosphatidylinositol 3-kinases - metabolism (1077) 1077
middle aged (1038) 1038
apoptosis - drug effects (1027) 1027
pi3k (1020) 1020
tumors (1001) 1001
cell proliferation (965) 965
mtor inhibitors (959) 959
care and treatment (956) 956
gene expression (953) 953
metabolism (951) 951
health aspects (944) 944
cells (929) 929
antineoplastic agents - pharmacology (913) 913
adult (897) 897
neurosciences (879) 879
physiological aspects (873) 873
tor serine-threonine kinases - genetics (873) 873
rats (870) 870
sirolimus - analogs & derivatives (841) 841
mtor inhibitor (817) 817
aged (812) 812
cell growth (801) 801
chemotherapy (800) 800
therapy (797) 797
mechanistic target of rapamycin complex 1 (795) 795
metastasis (771) 771
proliferation (753) 753
sirolimus - therapeutic use (753) 753
cell cycle (751) 751
cells, cultured (742) 742
antineoplastic agents - therapeutic use (729) 729
breast cancer (722) 722
biology (713) 713
mutation (706) 706
medicine, research & experimental (702) 702
survival (696) 696
protein kinase inhibitors - pharmacology (691) 691
akt protein (684) 684
signaling pathway (675) 675
genetic aspects (672) 672
autophagy - drug effects (669) 669
in-vitro (667) 667
kinase (664) 664
sirolimus (640) 640
cell line (631) 631
signal transduction - physiology (617) 617
development and progression (609) 609
mtor pathway (604) 604
protein kinases - metabolism (604) 604
mammalian target of rapamycin (593) 593
mice, inbred c57bl (586) 586
disease models, animal (585) 585
xenograft model antitumor assays (578) 578
research article (577) 577
breast-cancer (572) 572
immunology (568) 568
phosphatidylinositol 3-kinases - antagonists & inhibitors (566) 566
dose-response relationship, drug (563) 563
immunohistochemistry (554) 554
oxidative stress (554) 554
blotting, western (553) 553
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13767) 13767
French (102) 102
German (60) 60
Spanish (27) 27
Chinese (16) 16
Russian (15) 15
Korean (13) 13
Japanese (12) 12
Polish (10) 10
Czech (5) 5
Hungarian (5) 5
Turkish (3) 3
Slovak (2) 2
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cell, ISSN 1097-2765, 2011, Volume 44, Issue 2, pp. 304 - 316
DEPTOR, an inhibitor of mTORC1 and mTORC2, is degraded via ubiquitin-proteasome pathway by an unknown E3 ubiquitin ligase. Here we report that DEPTOR is a... 
CANCER-CELLS | TARGET | IN-VITRO | COMPLEX | PATHWAY | BIOCHEMISTRY & MOLECULAR BIOLOGY | F-BOX PROTEINS | DEGRADATION | CELL-GROWTH | KAPPA-B | PROMOTES | CELL BIOLOGY | mTOR | SCF E3 ligase | DEPTOR | Autophagy | βTrCP | survival
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2018, Volume 142, Issue 1, pp. 202 - 213
Mantle cell lymphoma (MCL) is an aggressive and incurable malignant disease. Despite of general chemotherapy, relapse and mortality are common, highlighting... 
mTOR inhibitor | targeted therapy | BTK inhibitor | drug combination | Mantle cell lymphoma | UNITED-STATES | ACTIVATION | PHOSPHORYLATION | PLUS RITUXIMAB | IBRUTINIB | PROLIFERATION | COMBINATION | ONCOLOGY | RESISTANCE | CHRONIC LYMPHOCYTIC-LEUKEMIA | SGK1 | Everolimus - pharmacology | Apoptosis - drug effects | Humans | Lymphoma, Mantle-Cell - drug therapy | Drug Synergism | TOR Serine-Threonine Kinases - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Cell Proliferation - drug effects | Mice | Acrylamides - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors | Proteins | Tyrosine | Chemotherapy | Analysis | Mortality | Phenols | Lymphomas | Drug therapy, Combination | Gene expression | Cancer | Drugs | Regulators | Animal models | Bax protein | AKT protein | Drug development | Kinases | B-cell receptor | Cyclin D1 | Caspase-3 | Phase transitions | Cyclin-dependent kinase 4 | Anticancer properties | Signal transduction | Antitumor agents | Bcl-x protein | Xenografts | Cell cycle | Inhibition | Mantle | G1 phase | Phase transformations | Poly(ADP-ribose) polymerase | Caspase | Pharmacology | Rapamycin | Lymphoma | Bruton's tyrosine kinase | Cyclin-dependent kinase 2 | Signaling | Inhibitors | Lymphocytes B | Cell lines | Bcl protein | Synergistic effect | Apoptosis | Index Medicus
Journal Article
Liver International, ISSN 1478-3223, 05/2013, Volume 33, Issue 5, pp. 780 - 793
Journal Article
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 08/2014, Volume 90, Issue 3, pp. 197 - 207
While PI3K/AKT/mTOR pathway is altered in a variety of cancers including non small cell lung cancer, abnormalities in this pathway are more common in squamous... 
mTOR | AKT | SQCLC | PI3K | NSCLC | MAMMALIAN TARGET | I PI3K INHIBITOR | ONCOGENE MUTATIONS | AKT INHIBITOR | ANTITUMOR-ACTIVITY | DOSE-ESCALATION | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | ADVANCED NSCLC | PHASE-I | MTOR INHIBITOR | Lung Neoplasms - drug therapy | TOR Serine-Threonine Kinases - metabolism | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Lung Neoplasms - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Neoplasm Proteins - metabolism | Enzyme Inhibitors - administration & dosage | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antineoplastic Agents - adverse effects | Proto-Oncogene Proteins c-akt - metabolism | Phosphatidylinositol 3-Kinase - metabolism | Enzyme Inhibitors - adverse effects | Molecular Targeted Therapy - adverse effects | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - metabolism | Enzyme Inhibitors - therapeutic use | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 05/2017, Volume 16, Issue 5, pp. 793 - 804
Journal Article
Journal Article
Liver International, ISSN 1478-3223, 04/2015, Volume 35, Issue 4, pp. 1451 - 1463
Background & Aims Mammalian target of rapamycin and angiotensin‐converting enzyme inhibition has been shown to have antifibrotic activity in models of liver... 
mTOR inhibitors | fibrosis | Mdr2 | ACE inhibitors | MTOR inhibitors | Fibrosis | RAPAMYCIN | BILE-DUCT | LIVER FIBROSIS | BILIARY FIBROSIS | HEPATIC-FIBROSIS | P-GLYCOPROTEIN | IN-VITRO | SCLEROSING CHOLANGITIS | SMOOTH-MUSCLE-CELLS | GASTROENTEROLOGY & HEPATOLOGY | SIROLIMUS | Liver - pathology | Liver - enzymology | Tetrazoles - pharmacology | Captopril - pharmacology | Species Specificity | TOR Serine-Threonine Kinases - metabolism | ATP Binding Cassette Transporter, Sub-Family B - deficiency | Male | Liver Cirrhosis, Experimental - drug therapy | Angiotensin II Type 1 Receptor Blockers - pharmacology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Liver Cirrhosis, Experimental - enzymology | Biphenyl Compounds - pharmacology | Liver - drug effects | Time Factors | Liver Cirrhosis, Experimental - pathology | Female | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Drug Therapy, Combination | Everolimus - pharmacology | Hydroxyproline - metabolism | Gene Expression Regulation | Liver Cirrhosis, Experimental - genetics | Sirolimus - pharmacology | Mice, Knockout | Animals | Signal Transduction - drug effects | Renin-Angiotensin System - drug effects | Protein Kinase Inhibitors - pharmacology | ATP Binding Cassette Transporter, Sub-Family B - genetics | Liver diseases | Captopril | Analysis | Angiotensin | Genetic research | Gene expression
Journal Article